It is important to note that ponatinib, a third generation BCR::ABL1 targeted therapy, can potently inhibit FLT3 receptor phosphorylation and cell proliferation in AML cells with an IC50 value comparable to that required for BCR::ABL1 inhibition [26]. Here, BCR is linked to acute myeloid leukemia.